Daniel O Scharfstein
Overview
Explore the profile of Daniel O Scharfstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1895
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Derington C, Berchie R, Scharfstein D, Andrews R, Greene T, Xu Y, et al.
J Gerontol A Biol Sci Med Sci
. 2025 Feb;
PMID: 39945185
Background: Whether the differing mechanistic effects between angiotensin-2 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) on the renin-angiotensin system translate to differential effects on clinical cognitive outcomes is unclear....
2.
Oral vs Intravenous Antibiotics for Fracture-Related Infections: The POvIV Randomized Clinical Trial
Obremskey W, OToole R, Morshed S, Tornetta 3rd P, Murray C, Jones C, et al.
JAMA Surg
. 2025 Jan;
160(3):276-284.
PMID: 39841468
Importance: Fracture-related infection (FRI) is a serious complication following fracture fixation surgery. Current treatment of FRIs entails debridement and 6 weeks of intravenous (IV) antibiotics. Lab data and retrospective clinical...
3.
Smith B, Gao Y, Yang S, Varadhan R, Apter A, Scharfstein D
Biometrics
. 2024 Dec;
80(4.
PMID: 39723564
Many trials are designed to collect outcomes at or around pre-specified times after randomization. If there is variability in the times when participants are actually assessed, this can pose a...
4.
Apter A, Barg F, Basu S, Federman A, Hamilton W, Krishnan J, et al.
Trials
. 2024 Dec;
25(1):841.
PMID: 39702510
Deviation from protocolized assessment times is commonplace in pragmatic randomized clinical trials. Working with a stakeholder advisory board for a Patient-Centered Outcomes Research Institute®-funded project on statistical methods for handling...
5.
Hunt 3rd L, Murimi I, Segal J, Seamans M, Scharfstein D, Varadhan R
J R Stat Soc Ser A Stat Soc
. 2024 Nov;
183(4):1461-1478.
PMID: 39512652
Whereas generic drugs offer a cost-effective alternative to brand name drugs, regulators need a method to assess therapeutic equivalence in a post-market setting. We develop such a method in the...
6.
Nabi R, Bonvini M, Kennedy E, Huang M, Smid M, Scharfstein D
Biometrics
. 2024 Oct;
80(4).
PMID: 39400259
Establishing cause-effect relationships from observational data often relies on untestable assumptions. It is crucial to know whether, and to what extent, the conclusions drawn from non-experimental studies are robust to...
7.
Kelley A, Incze M, Baumgartner M, Campbell A, Nunes E, Scharfstein D
Drug Alcohol Depend
. 2024 Jun;
261:111368.
PMID: 38896944
Background: High levels of missing outcome data for biologically confirmed substance use (BCSU) threaten the validity of substance use disorder (SUD) clinical trials. Underlying attributes of clinical trials could explain...
8.
Nguyen T, Stuart E, Scharfstein D, Ogburn E
Stat Med
. 2024 Jun;
43(19):3664-3688.
PMID: 38890728
An important strategy for identifying principal causal effects (popular estimands in settings with noncompliance) is to invoke the principal ignorability (PI) assumption. As PI is untestable, it is important to...
9.
Chapman A, Scharfstein D, Montgomery A, Byrne T, Suo Y, Effiong A, et al.
AMIA Annu Symp Proc
. 2024 Jan;
2023:894-903.
PMID: 38222404
The Electronic Health Record (EHR) contains information about social determinants of health (SDoH) such as homelessness. Much of this information is contained in clinical notes and can be extracted using...
10.
King J, Berchie R, Derington C, Marcum Z, Scharfstein D, Greene T, et al.
J Am Heart Assoc
. 2023 Aug;
12(17):e030311.
PMID: 37646208
BACKGROUND Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) block distinct components of the renin-angiotensin system. Whether this translates into differential effects on cardiovascular disease events remains unclear....